Back to Awarded Treatment Trials


Awarded Trial: 99-128

Grant ID

99-128

Illness

Bipolar Disorder

Primary Drug/Intervention

Pramipexole

Primary Dosage

Mean dose = 1.7 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Goldberg

Sample Size

60

Duration of Study Period for Each Subject

6 weeks

Outcome Measurements

HDRS, CGI

Results

Twenty-two patients with bipolar depression received the anti-parkison?s drug pramipexole or placebo. Sixty-seven percent of patients receiving the drug had a 50% reduction in symptoms, whereas only 20% of patients receiving placebo improved to a similar degree.

Publication

Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. American Journal of Psychiatry 2004;161:564-566.

Link

http://www.ncbi.nlm.nih.gov/pubmed/14992985

PI Name

Joseph Goldberg

Degree

MD

Center

Payne Whitney Clinic, New York Presbyterian Hospital

Institution

Cornell University Medical College

Address

525 E. 68th Street, Box 140

City or Town

New York

State or Province

NY

Zip or Postal Code

10021

Country

USA

Email Address

jfgoldbe@mail.med.cornell.edu